Notice of Allowability	Application No.	Applicant(s)
	10/624,822	GHOSHAL ET AL.
	Examiner	Art Unit
	Shafiqul Haq	1641
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.		
1. This communication is responsive to <u>amendments and arguments filed 2/15/07</u> .		
2. The allowed claim(s) is/are 3-5 and 10-11, now renumbered as 1-5.		
 3. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some* c) None of the: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)). * Certified copies not received: Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements 		
noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		
4. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
5. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.		
(a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached		
1) hereto or 2) to Paper No./Mail Date		
(b) including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date		
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).		
6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
·		·
Attachment(s)	<u> </u>	
1. Notice of References Cited (PTO-892)	5. Notice of Informal P	_ ' '
2. Notice of Draftperson's Patent Drawing Review (PTO-948)	6. ⊠ Interview Summary Paper No./Mail Dat	e <u>4/17/07</u> .
3. Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date	7. 🛛 Examiner's Amendn	nent/Comment
4. Examiner's Comment Regarding Requirement for Deposit of Biological Material	8. Examiner's Stateme	ent of Reasons for Allowance
-	9.	

Application/Control Number: 10/624,822 Page 2

Art Unit: 1641

DETAILED ACTION

1. The terminal disclaimer filed on 2/15/07 disclaiming the terminal portion of any patent granted on this application which would extend beyond the expiration date of Patent No. 6,653,456 has been reviewed and is accepted. The terminal disclaimer has been recorded.

2. Double patenting rejection of 9/20/06 has been withdrawn in view of the Terminal Disclaimer filed 2/15/07.

Examiner's amendment

3. Authorization for this examiner's amendment was given in a telephone interview with Marilyn L. Amick on April 17, 2007.

4. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

5. Claim 3 has been amended as follows:

In claim 3, line 3, replace the words "a reagent of", with the words --an aminoglycoside analog having--.

In claim 3, line 8, after "in only one of G' or Y';" replace the words "the reagent comprising the analyte analog of the aminoglycoside and forming", with the words -- and wherein the animoglycoside analog and the aminoglycoside in the sample compete to form--

6. Claim 5 has been amended as follows:

In claim 5, last line, after the formula, insert a period.

7. Claim 10 has been amended as follows:

In claim 10, line 2, replace the words "a reagent of", with the words --an aminoglycoside analog having--

8. Claim 11 has been amended as follows:

In claim 11, last line, after the formula, insert a period.

Conclusion

9. Claims 3-5 and 10-11, now renumbered as 1-5 are allowed.

10. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Shafiqul Haq whose telephone number is 571-272-6103. The examiner can normally be reached on 7:30AM-4:00PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Long V. Le can be reached on 571-272-0823. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Art Unit: 1641

EXAMINER

ART UNIT 1641

LONG V. LE

04/30/07 SUPERVISORY PATENT EXAMINER

ART UNIT 1641